Skandinaviska Enskilda Banken Ab (Publ) Akero Therapeutics, Inc. Transaction History
Skandinaviska Enskilda Banken Ab (Publ)
- $19.9 Billion
- Q1 2025
A detailed history of Skandinaviska Enskilda Banken Ab (Publ) transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Skandinaviska Enskilda Banken Ab (Publ) holds 7,676 shares of AKRO stock, worth $388,098. This represents 0.0% of its overall portfolio holdings.
Number of Shares
7,676Holding current value
$388,098% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding AKRO
# of Institutions
273Shares Held
86MCall Options Held
1.02MPut Options Held
823K-
Rtw Investments, LP New York, NY7.42MShares$375 Million4.92% of portfolio
-
Janus Henderson Group PLC London, X07.07MShares$357 Million0.16% of portfolio
-
Wellington Management Group LLP Boston, MA5.94MShares$300 Million0.05% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$282 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$265 Million7.15% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $2.35B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...